MCID: LCR001
MIFTS: 34

Lacrimal Duct Obstruction malady

Categories: Eye diseases

Aliases & Classifications for Lacrimal Duct Obstruction

Aliases & Descriptions for Lacrimal Duct Obstruction:

Name: Lacrimal Duct Obstruction 12 42 14
Obstruction of Lacrimal Canaliculus 12
Obstruction of Lacrimal Ducts 12
Blocked Lacrimal Canaliculus 12

Classifications:



External Ids:

Disease Ontology 12 DOID:13929
MeSH 42 D007767
NCIt 47 C34757
UMLS 69 C0022906

Summaries for Lacrimal Duct Obstruction

MalaCards based summary : Lacrimal Duct Obstruction, also known as obstruction of lacrimal canaliculus, is related to growth retardation, deafness, femoral epiphyseal dysplasia, and lacrimal duct obstruction and deafness, epiphyseal dysplasia, short stature. An important gene associated with Lacrimal Duct Obstruction is DCXR (Dicarbonyl And L-Xylulose Reductase), and among its related pathways/superpathways is Hypothetical Craniofacial Development Pathway. The drugs Menthol and Ephedrine have been mentioned in the context of this disorder. Affiliated tissues include eye, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and craniofacial

Related Diseases for Lacrimal Duct Obstruction

Diseases related to Lacrimal Duct Obstruction via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 32)
id Related Disease Score Top Affiliating Genes
1 growth retardation, deafness, femoral epiphyseal dysplasia, and lacrimal duct obstruction 12.1
2 deafness, epiphyseal dysplasia, short stature 11.1
3 lacrimal duct defect 11.1
4 branchiooculofacial syndrome 11.0
5 corticosterone methyloxidase deficiency 10.2 EYA1 SIX1
6 intermediate cell type ciliary body melanoma 10.2 DCXR OPTN
7 hemometra 10.2 DCXR OPTN
8 emery-dreifuss muscular dystrophy 5, autosomal dominant 10.2 EYA1 SIX1
9 opisthorchiasis 10.2 DCXR OPTN
10 rhizomelic chondrodysplasia punctata spectrum 10.2 EYA1 SIX1
11 periostitis 10.1 DCXR PGRMC1
12 clcn7-related osteopetrosis 10.1 EYA1 SIX1 SIX5
13 otofaciocervical syndrome 10.1 EYA1 SIX1 SIX5
14 retinitis pigmentosa 63 10.1 EYA1 SIX1 SIX5
15 warburg micro syndrome 10.1 EYA1 SIX1 SIX5
16 hereditary angioedema 10.1 EYA1 SIX1 SIX5
17 question mark ears, isolated 10.1 EYA1 SIX5 TFAP2A
18 pancreatic agenesis 2 10.1 EYA1 SIX1 SIX5
19 b- and t-cell mixed leukemia 10.1 DCXR PGRMC1
20 baraitser-winter syndrome 10.1 OPTN SATB2
21 joubert syndrome 6 10.1 MBD5 OPTN
22 hereditary spherocytosis 10.0 DCXR MBD5 SATB2
23 hypomyelinating leukodystrophy 13 10.0 SATB2 TP63
24 ampulla of vater clear cell adenocarcinoma 10.0 DCXR MBD5
25 gaze palsy, horizontal, with progressive scoliosis 10.0 SATB2 TP63
26 adult syndrome 10.0 SATB2 TP63
27 rosacea conjunctivitis 10.0 IL17A TP63
28 cornelia de lange syndrome 5 9.9 OPTN SATB2 TFAP2A
29 differentiated thyroid carcinoma 9.9 SATB2 TP63
30 orofacial cleft 6 9.9 SATB2 TFAP2A TP63
31 dacryocystitis 9.7
32 amenorrhea 8.5 DCXR EYA1 IL17A MBD5 OPTN PGRMC1

Graphical network of the top 20 diseases related to Lacrimal Duct Obstruction:



Diseases related to Lacrimal Duct Obstruction

Symptoms & Phenotypes for Lacrimal Duct Obstruction

GenomeRNAi Phenotypes related to Lacrimal Duct Obstruction according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.28 TGFB1 IL17A PGRMC1 SATB2
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.28 TGFB1 TP63 IL17A PGRMC1 SATB2

MGI Mouse Phenotypes related to Lacrimal Duct Obstruction:

44 (show all 13)
id Description MGI Source Accession Score Top Affiliating Genes
1 craniofacial MP:0005382 10.11 EYA1 IL17A MBD5 SATB2 SIX1 TFAP2A
2 endocrine/exocrine gland MP:0005379 10.11 SIX1 SIX5 TFAP2A TGFB1 TP63 EYA1
3 cardiovascular system MP:0005385 10.07 EYA1 MBD5 SATB2 SIX1 TFAP2A TGFB1
4 digestive/alimentary MP:0005381 10.04 EYA1 IL17A SATB2 SIX1 TFAP2A TGFB1
5 growth/size/body region MP:0005378 10.03 EYA1 IL17A MBD5 SATB2 SIX1 TFAP2A
6 mortality/aging MP:0010768 10.02 EYA1 IL17A MBD5 OPTN SATB2 SIX1
7 embryo MP:0005380 9.95 EYA1 SATB2 SIX1 TFAP2A TGFB1 TP63
8 limbs/digits/tail MP:0005371 9.8 SIX1 TFAP2A TP63 MBD5 SATB2
9 respiratory system MP:0005388 9.8 EYA1 IL17A SATB2 SIX1 TFAP2A TGFB1
10 skeleton MP:0005390 9.76 EYA1 IL17A MBD5 SATB2 SIX1 TFAP2A
11 renal/urinary system MP:0005367 9.72 EYA1 IL17A SIX1 TGFB1 TP63
12 taste/olfaction MP:0005394 9.13 PGRMC1 SIX1 TP63
13 vision/eye MP:0005391 9.1 SIX5 TFAP2A TGFB1 TP63 EYA1 SIX1

Drugs & Therapeutics for Lacrimal Duct Obstruction

Drugs for Lacrimal Duct Obstruction (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 33)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Menthol Approved Phase 4 2216-51-5 16666
2
Ephedrine Approved Phase 1, Phase 2 299-42-3 9294
3
Lidocaine Approved, Vet_approved Phase 1, Phase 2 137-58-6 3676
4
Pseudoephedrine Approved Phase 1, Phase 2 90-82-4 7028
5
Tetracaine Approved, Vet_approved Phase 1, Phase 2 94-24-6 5411
6 Anesthetics Phase 1, Phase 2
7
Dexamethasone Approved, Investigational, Vet_approved Phase 1 50-02-2 5743
8
Docetaxel Approved May 1996, Investigational Phase 1 114977-28-5 148124 9877265
9 Dexamethasone acetate Phase 1 1177-87-3
10 glucocorticoids Phase 1
11
protease inhibitors Phase 1
12 Gastrointestinal Agents Phase 1
13 HIV Protease Inhibitors Phase 1
14 Hormone Antagonists Phase 1
15 Dexamethasone 21-phosphate Phase 1
16 Hormones Phase 1
17 Peripheral Nervous System Agents Phase 1
18 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 1
19 Antiemetics Phase 1
20 Anti-Inflammatory Agents Phase 1
21 Antimitotic Agents Phase 1
22 BB 1101 Phase 1
23 Autonomic Agents Phase 1
24 Antineoplastic Agents, Hormonal Phase 1
25
Iodine 7553-56-2 807
26 cadexomer iodine
27 Trace Elements
28 Anti-Infective Agents
29 Anti-Infective Agents, Local
30 Micronutrients
31 Ether
32 Mitomycins
33 Calamus Nutraceutical

Interventional clinical trials:

(show all 12)
id Name Status NCT ID Phase
1 A Comparison of Endonasal Dacryocystorhinostomy With and Without Silicone Tubes Completed NCT00784992 Phase 4
2 Study of Surgical Procedures for Treatment of Persistent Nasolacrimal Duct Obstruction in Children < 4 Years Old Completed NCT00315315 Phase 3
3 A Comparative Study of Two Endoscopic Operations for Lacrimal Duct Obstruction Recruiting NCT02636257 Phase 1, Phase 2
4 Prevention of Docetaxel Induced Dacryostenosis Completed NCT00266838 Phase 1
5 Lacrimal Drainage System Obstruction Associated to Radioactive Iodine Therapy for Thyroid Carcinoma Unknown status NCT01579344
6 Analysis of 86 Dacryoliths at the University Hospital Ostrava Completed NCT01826734
7 Lacrimal Drainage Resistance Study Completed NCT01766232
8 The Factors That Affected the Outcome of Treatment of Congenital Nasolacrimal Duct Obstruction Completed NCT02081781
9 Lid Margin And Conjunctival Microbial Flora Following Punctum Occlusion Completed NCT00735865
10 Risk and Importance of Peroperative Nasal Hemorrhage in the Treatment of Lacrimal Duct Obstruction in Young Children Recruiting NCT02851641
11 Endo-nasal Endoscopic DCR and External-DCR in Primary Nasolacrimal Duct Obstruction Recruiting NCT02993770
12 Endoscopic Dacryocystorhinostomy Prospective Research Active, not recruiting NCT00571129

Search NIH Clinical Center for Lacrimal Duct Obstruction

Cochrane evidence based reviews: lacrimal duct obstruction

Genetic Tests for Lacrimal Duct Obstruction

Anatomical Context for Lacrimal Duct Obstruction

MalaCards organs/tissues related to Lacrimal Duct Obstruction:

39
Eye

Publications for Lacrimal Duct Obstruction

Articles related to Lacrimal Duct Obstruction:

(show all 13)
id Title Authors Year
1
Factors Associated with the Efficacy of Probing for Adult Patients with Lacrimal Duct Obstruction. ( 27015237 )
2016
2
Relationship between frequent swimming pool use and lacrimal duct obstruction. ( 24112783 )
2013
3
Direct endoscopic probing for congenital lacrimal duct obstruction. ( 23566023 )
2013
4
Transcanalicular approach to adult lacrimal duct obstruction: a review of instruments and methods. ( 19320304 )
2009
5
Uncommon presentation of congenital lacrimal duct obstruction a case report of congenital amniontocele. ( 22400096 )
2007
6
Eosinophilic angiocentric fibrosis: an unusual entity producing complete lacrimal duct obstruction. ( 16754230 )
2006
7
The clinical value of dacryoscintigraphy in the selection of surgical approach for patients with functional lacrimal duct obstruction. ( 16248384 )
2005
8
Diagnostic Ophthalmology. Left dacryocystitis with naso-lacrimal duct obstruction. ( 15600163 )
2004
9
Dilatation and stenting for naso-lacrimal duct obstruction: a pilot project. ( 10551300 )
1999
10
Bacteriology of lacrimal duct obstruction in adults. ( 9135406 )
1997
11
Silicone intubation for the treatment of congenital lacrimal duct obstruction: successful results removing the tubes after six weeks. ( 3211482 )
1988
12
CORTICOSTEROIDS AND FIBROLYSIN IN THE PREVENTION OF LACRIMAL DUCT OBSTRUCTION. ( 18170750 )
1962
13
The management of lacrimal duct obstruction. ( 14824621 )
1951

Variations for Lacrimal Duct Obstruction

Expression for Lacrimal Duct Obstruction

Search GEO for disease gene expression data for Lacrimal Duct Obstruction.

Pathways for Lacrimal Duct Obstruction

Pathways related to Lacrimal Duct Obstruction according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1 9.53 TFAP2A TP63

GO Terms for Lacrimal Duct Obstruction

Cellular components related to Lacrimal Duct Obstruction according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 9.32 DCXR EYA1 MBD5 OPTN SATB2 SIX1
2 transcription factor complex GO:0005667 9.13 SATB2 SIX1 TP63

Biological processes related to Lacrimal Duct Obstruction according to GeneCards Suite gene sharing:

(show all 27)
id Name GO ID Score Top Affiliating Genes
1 transcription from RNA polymerase II promoter GO:0006366 9.93 SATB2 SIX1 TFAP2A TP63
2 negative regulation of transcription, DNA-templated GO:0045892 9.88 SIX5 TFAP2A TGFB1 TP63
3 negative regulation of transcription from RNA polymerase II promoter GO:0000122 9.85 SATB2 SIX1 TFAP2A TGFB1 TP63
4 positive regulation of transcription, DNA-templated GO:0045893 9.83 EYA1 SIX1 TFAP2A TGFB1 TP63
5 regulation of gene expression GO:0010468 9.77 SATB2 SIX1 TGFB1
6 sensory perception of sound GO:0007605 9.71 EYA1 SIX1 TFAP2A
7 branching involved in ureteric bud morphogenesis GO:0001658 9.63 EYA1 SIX1
8 cell death GO:0008219 9.62 IL17A OPTN
9 positive regulation of Notch signaling pathway GO:0045747 9.61 EYA1 TP63
10 positive regulation of bone mineralization GO:0030501 9.61 TFAP2A TGFB1
11 embryonic cranial skeleton morphogenesis GO:0048701 9.6 SIX1 TFAP2A
12 regulation of neuron differentiation GO:0045664 9.58 EYA1 SIX1
13 cochlea morphogenesis GO:0090103 9.57 EYA1 SIX1
14 middle ear morphogenesis GO:0042474 9.56 EYA1 SIX1
15 positive regulation of branching involved in ureteric bud morphogenesis GO:0090190 9.55 SIX1 TGFB1
16 inner ear morphogenesis GO:0042472 9.54 EYA1 SIX1 TFAP2A
17 pharyngeal system development GO:0060037 9.52 EYA1 SIX1
18 neuron fate specification GO:0048665 9.51 EYA1 SIX1
19 pattern specification process GO:0007389 9.5 EYA1 SIX1 TP63
20 anatomical structure development GO:0048856 9.49 EYA1 SIX1
21 aorta morphogenesis GO:0035909 9.48 EYA1 SIX1
22 embryonic skeletal system morphogenesis GO:0048704 9.43 EYA1 SATB2 SIX1
23 otic vesicle development GO:0071599 9.4 EYA1 SIX1
24 positive regulation of transcription from RNA polymerase II promoter GO:0045944 9.23 EYA1 IL17A SATB2 SIX1 SIX5 TFAP2A
25 positive regulation of secondary heart field cardioblast proliferation GO:0072513 9.16 EYA1 SIX1
26 ureteric bud development GO:0001657 9.13 EYA1 SIX1 TGFB1
27 multicellular organism development GO:0007275 10.02 EYA1 SATB2 SIX1 SIX5 TP63

Molecular functions related to Lacrimal Duct Obstruction according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 RNA polymerase II core promoter proximal region sequence-specific DNA binding GO:0000978 9.56 SATB2 SIX1 SIX5 TFAP2A
2 sequence-specific DNA binding GO:0043565 9.55 SATB2 SIX1 SIX5 TFAP2A TP63
3 transcription regulatory region DNA binding GO:0044212 9.5 SIX1 TFAP2A TP63
4 transcriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific binding GO:0001077 9.26 SATB2 SIX1 TFAP2A TP63
5 chromatin binding GO:0003682 9.02 MBD5 SATB2 SIX1 TFAP2A TP63

Sources for Lacrimal Duct Obstruction

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....